StockData
CVMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends September 30

CEL SCI CORP

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.65−0.14 (-7.82%)

Close on Oct 19, 2026

Market cap
$19.99M
P/E (TTM)
–
Dividend yield
–

CEL SCI CORP revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Cel Sci does not break out revenue by segment, region or product in the tagged data of its filings for this period type.